What does Greenwich LifeSciences, Inc. do?
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast…
What is Greenwich LifeSciences, Inc.'s P/E and P/B ratio?
Greenwich LifeSciences, Inc. has a P/E ratio of -10.1 and a P/B ratio of 72.90.
What is Greenwich LifeSciences, Inc.'s debt-to-equity ratio?
Greenwich LifeSciences, Inc. has a debt-to-equity ratio of 0.00.
How much does Greenwich LifeSciences, Inc. owe compared with what it owns?
Greenwich LifeSciences, Inc. owes $0.65 for every $1 it owns (balance sheet Jun 2026), which is moderate.
What is Greenwich LifeSciences, Inc.'s Positivity rank?
Greenwich LifeSciences, Inc. is ranked #6,324 of 6,775 companies globally and #3,608 of 4,000 in United States on PositoAI, with a Positivity Score of -13,212.
Does Greenwich LifeSciences, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
Greenwich LifeSciences, Inc. has no active red flags. It has 1 yellow flag (PosiYellow stress signals, 4/10 points): Annual report filed late (NT 10-K).
Where can I read the latest news about Greenwich LifeSciences, Inc.?
Recent headlines about Greenwich LifeSciences, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Greenwich LifeSciences, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Greenwich LifeSciences, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.